Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report

Rittmeyer, 2017, Atezolizumab versus Docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N Engl J Med, 378, 2288, 10.1056/NEJMoa1716948 West, 2019, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a Multicentre, Randomised, Open-label, phase 3 Trial, Lancet Oncol, 20, 924, 10.1016/S1470-2045(19)30167-6 Ibraheim, 2019, Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors, Rheumatology, 58, vii17, 10.1093/rheumatology/kez465 Postow, 2015, Managing immune checkpoint-blocking antibody side effects, Am Soc Clin Oncol Educ Book, 76, 10.14694/EdBook_AM.2015.35.76 Zen, 2019, Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy, Semin Diagn Pathol, 36, 434, 10.1053/j.semdp.2019.07.009 Onoyama, 2020, Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review, World J Gastroenterol, 26, 353, 10.3748/wjg.v26.i3.353 Isayama, 2018, Clinical guidelines for primary Sclerosing Cholangitis 2017, J Gastroenterol, 53, 1006, 10.1007/s00535-018-1484-9